IQVIA (NYSE:IQV) Downgraded to Hold Rating by TD Cowen

IQVIA (NYSE:IQV) was downgraded by equities researchers at TD Cowen from a “buy” rating to a “hold” rating in a report issued on Monday,Finviz reports. They currently have a $215.00 price target on the medical research company’s stock. TD Cowen’s price target points to a potential downside of 0.66% from the company’s previous close.

IQV has been the topic of a number of other reports. Truist Financial restated a “buy” rating and issued a $265.00 price objective (up from $235.00) on shares of IQVIA in a report on Wednesday, October 29th. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the company from $195.00 to $235.00 in a report on Thursday, October 9th. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Citigroup increased their target price on shares of IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $239.94.

IQVIA Price Performance

IQVIA stock opened at $216.43 on Monday. The firm has a market cap of $36.86 billion, a PE ratio of 29.69, a price-to-earnings-growth ratio of 2.42 and a beta of 1.34. IQVIA has a 52-week low of $134.65 and a 52-week high of $225.91. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The company’s 50 day moving average is $197.12 and its two-hundred day moving average is $174.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same period last year, the business earned $2.84 EPS. The company’s revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, research analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Canada Pension Plan Investment Board grew its position in IQVIA by 7.3% during the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after purchasing an additional 312,807 shares during the last quarter. Alliancebernstein L.P. grew its position in IQVIA by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after purchasing an additional 19,573 shares during the last quarter. Artisan Partners Limited Partnership acquired a new stake in shares of IQVIA in the 2nd quarter worth $515,772,000. JPMorgan Chase & Co. lifted its stake in shares of IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock worth $492,659,000 after acquiring an additional 581,157 shares during the period. Finally, Nordea Investment Management AB lifted its stake in shares of IQVIA by 12.3% in the 3rd quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock worth $421,257,000 after acquiring an additional 253,759 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.